InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,283.60
(
-0.64%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.89
(
-0.14%
)
Bitcoin
64,861.54
(
0.06%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

lgonber

Send PM Follow Ignore
Followers 12
Posts 648
Boards Moderated 0
Alias Born 12/20/2014

lgonber

Re: None

Friday, 12/22/2017 3:10:39 AM

Friday, December 22, 2017 3:10:39 AM

Post# of 252279
M&A: Roche Buys RXDX to strength oncology pipeline. 74% premium
• Looking to broaden its oncology portfolio, Swiss healthcare firm Roche (OTCQX:RHHBY) is buying U.S. cancer drugmaker Ignyta (NASDAQ:RXDX) for $1.7B.
• Roche will pay $27 per share for Ignyta, representing a premium of about 74% to the stock's closing price on Thursday.
• The U.S. company has a suite of drugs in early stage development that use gene therapy to kill off underlying diseases that drive cancer tumor growth.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up